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THE PURGATORY in which liver trans-plantation was mired has ended in the 
cyclosporine era. Long-term survival after 
liver replacement was achieved in 1964 with 
dogs I and in humans2 beginning in 1967. The 
longest surviving patient is now in her 14th 
postoperative year. 
In spite of such tantalizing successes, the 
operation was unpredictable and unreliable, 
with I-year survival rates that did not im-
prove with increased experience over a 16-
year period. 3 Of the first III patients, 
less than 1/3 lived for 1 year. The I-year 
survival rose to 50% in a second but small 
series of 30 patients, but in a third series, the 
survival sank again, almost to the original 
level. The overall I-year survival rate for 170 
patients was 33%. 
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MATERIALS AND METHODS 
We have used cyclosporine (esA) with prednisone in 
all liver transplantations since early 1980. J The standard 
therapy begins with a 5-day burst of steroids, leveling off 
at about 20 mgjday in adults after a few days. The dose of 
esA is 6 mgjkg i.v. or 17 mg/kg orally. When nephrotox-
icity of esA is suspected, the esA dose is reduced; in a 
few instances it has been replaced temporarily with 
azathioprine. 
RESULTS 
The survival in the first 67 consecutive 
recipients in the cyclosporine era is summa-
rized in Fig. 1 and contrasted with the pooled 
previous experience. All of the CsA patients in 
Fig. 1 had their operations before May 1, 
1982, and thus have minimum I-year follow-
ups. The I-year and subsequent survival was 
doubled overnight compared to past expecta-
tions. 
Of the first 67 recipients in the CsA series 
treated over a period of <2 years, 42 passed 
the I-year mark. This was almost as many 
survivors as had been acquired in the nearly 
17 preceding years. Six of the 42 one-year 
survivors subsequently died. In four, the cause 
of the late failure was recurrence of the origi-
nal disease (two hepatic malignancies, one 
example each of Budd-Chiari syndrome and 
B-virus chronic hepatitis) (Table 1). The 
other late deaths were caused by an airway 
obstruction secondary to an upper respiratory 
infection in one patient and by complications 
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Fig. 1. Life survival curves of patients under con-
ventional immunosuppression vs. CsA-steroid therapy. 
In the latter group, note that survival after 1 year is 
actuarial. 
after retransplantation in a patient whose first 
graft was chronically rejected (Table 1). In 
spite of these six deaths after 1 year, the late 
decline of the life-survival curve has been 
slower than in past patients who entered the 
second postoperative year under azathioprine 
and prednisone (Fig. 1). 
A natural question would be whether these 
results could be explained by a sudden change 
in candidacy criteria or by a difference in the 
diseases for which transplantation was per-
formed. Analysis according to the recipient 
diseases showed that this was not the case. 
Instead, the results with almost all of the 
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Table 1. late Deaths Under Cyclosporine-Steroid 
Therapy 
Time 
Original DiagnOSis Cause of Death (Months) 
Chronic active hepatitis Airway obstruction, 12 
tonsillitis 
Cholangiocarcinoma Recurrent cancer 13 
Budd-Chiari syndrome Recurrent Budd-Chiari 15 
syndrome 
Chronic active hepatitis Recurrent chronic active 15 
hepatitis (B virus) 
Budd-Chiari syndrome After retransplantation 20 
(for chronic rejection) 
Hepatoma (fibrolamel- Recurrent cancer 33 
lar) 
diseases were improved (Table 2). This was 
obvious with all the diagnoses that contrib-
uted heavily to the case material before and 
after the introduction of cyclosporine, such as 
biliary atresia, nonalcoholic cirrhosis, primary 
hepatic malignancy, primary biliary cirrhosis, 
and the heterogenous group of inborn errors of 
metabolism. 
With these improved results, the pace of 
liver transplantation has quickened. Between 
1963 and the end of 1979, the average yearly 
caseload was not much over a dozen. The 
number of transplantations rose to 30 in 1981 
and to 80 in 1982 (Table 3). In the first 4 
months of 1983, 34 liver replacements were 
Table 2. Influence of Disease on '-Year Survival in 237 Patients· 
Conventional Therapy 
No. After 1 Yeart No. 
Biliary atresia 51 14 (27.0%) 11 
Nonalcoholic cirrhosis 46 16 (34.8%) 16 
Primary liver malignancy 18 5 (27.8%) 9 
Inborn errors§ 15 8 (53.3%) 10 
Alcoholic cirrhosis 15 4 (26.7%) 0 
Primary biliary cirrhosis 6 1 (16.7%) 6 
Sclerosing cholangitis 7 2 (28.6%) 3 
Secondary biliary cirrhosis 4 3 (75.0%) 5 
Budd-Chiari syndrome 1 1 (100.0%) 3 
Miscellaneous II 7 2 (28.6%) 4 
*The same case material was analyzed in detail elsewhere: but with shorter follow-ups. 
t32 of these 52 patients are still alive with follow-ups of 3%-13% years. 
p6 of these 42 patients are still alive with follow-ups of 1-3 Yo years. 
Cyclosporine + Steroids 
After 1 Yeart 
6 (54.5%) 
9 (56.3%) 
6 (66.7%) 
7 (70.0%) 
5 (83.3%) 
2 (66.7%) 
1 (20.0%) 
3 (100.0%) 
3 (75.0%) 
§Alpha-1-antitrypsin deficiency (17 examples), Wilson's disease (3). tyrosinemia (2), glycogen storage disease (2), sea blue 
histiocyte syndrome (1). 
II Neonatal hepatitis (3 examples). congenital hepatic fibrosis (2), Byler's disease (2). adenomatosis (1). hem achromatosis 
(1), protoporphyria (1). acute hepatitis B (1). 
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Table 3. Yearly Total of Orthotopic liver 
Transplantations 
Year No. of New Patients Retransplantation Total 
1963 5 0 5 
1966 0 
1967 6 0 6 
1968 12 2 14 
1969 6 1 7 
1970 10 1 11 
1971 11 0 11 
1972 11 1 12 
1973 13 4 17 
1974 20 21 
1975 9 4 13 
1976 14 3 17 
1977 21 2 23 
1978 19 2 21 
1979 11 0 11 
1980 15 0 15 
1981 26 4 30 
1982 62 18 80 
1983· 24 10 34 
Total 296 53 349 
• January-April, 1983. 
done, a rate that extrapolates to 100 for this 
year. 
To be a service, a new surgical procedure 
must be within the capability of more than the 
occasional surgeon. Until 1982, virtually all 
our liver transplantation procedures over a 
span of 19 years were performed by a single 
surgeon. During 1982, 40% of the procedures 
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were performed by another young faculty 
member or by the fellows, and this year this 
figure has been 70% (Table 3). 
In 1983, most of the adult patients have had 
pump-driven non heparin venovenous bypasses 
during the anhepatic phase, when the portal 
vein and vena caval systems must be 
obstructed. This simple technique has 
removed the urgency of the implantatio'n and 
should place the operation of liver replace-
ment within the grasp of a much greater 
number of surgeons. 
We have had one example of multiple intes-
tinal "lymphomatosis" in a liver recipient 6 
months postoperatively. His cyclosporine dose 
was dropped from 20 mg/kg/day to 1.4 mg/ 
kg/day, and the steroid dose was reduced 
from 25 mg/day to 10 mg/day. After several 
months on these almost homeopathic drug 
doses, he began to reject his liver, necessitat-
ing resumption of more standard immunosup-
pressive therapy (Fig. 2). The rejection was 
easily controlled, and this boy has returned to 
his university studies; he has no evidence of 
lymphoma. At autopsy, one other liver recip-
ient had similar lymphoproliferative lesions as 
an incidental finding. 
DISCUSSION 
Most of the mortality that remains with 
liver transplantation is perioperative and is 
aT 237 
17 yo cJ 
wI. 76.5-77 kg 
Fig. 2. Course of a 17-
year-old boy with chronic ac-
tive hepatitis, who developed 
"pseudo lymphomas" of the 
small intestine. Note that im-
munosuppression was drasti-
cally reduced, followed by evi-
dence of rejection, which was 
easily reversed. The patient is 
now well and without evidence 
of malignant disease. 
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Table 4. Change in Pattern of Surgeons Performing Liver Transplantation Since Introduction of Cyclosporine 
1963-1979 
New patients 170 
Total transplantations 191 
Transplantations by single surgeon (T. E. 187 
Starzl) (97.9%) 
related to technical surgical errors, to inadver-
tent use of damaged homografts, and to con-
tinuing acceptance into candidacy of patients 
who are moribund and with irreversible 
pathophysiology of other organ systems. 
One of the recent developments that may 
further reduce perioperative mortality is the 
non heparin venovenous bypass system now 
being used for almost all adult recipients. 
Aside from reducing the stresses to the operat-
ing surgeon, an extra incentive to use the 
bypass is the protection to the recipient kid-
neys offered by avoidance of inferior vena 
caval occlusion. This will be important 
because it may be that a physiologic or 
mechanical renal injury could amplify the 
potential nephrotoxicity of cyclosporine. In 
liver recipients, the necessity to juggle the 
CsA doses in the face of renal failure may 
force a decision to switch temporarily to aza-
thioprine.3 Starting the postoperative period 
with good renal function is one of the premoni-
tors of success. 
When CsA was first used clinically, the 
appearance of lymphomas in an alarming 
number of patients cast a shadow over the fate 
of this new drug. As it has turned out, the 
mere chronicling of these so-called lympho-
1980-1981 1982 1983 (4 months) 
40 62 24 
45 80 34 
45 48 10 
(100%) (60%) (29.4%) 
mas is a relatively meaningless exercise. The 
lesions are almost always a manifestation of 
Epstein-Barr virus infection,4 and thus they 
imply overimmunosuppression. More impor-
tant, virtually all the lymphoproliferative 
lesions (lwatsuki has appropriately called 
them pseudolymphomas5) can be expected to 
involute spontaneously providing immunosup-
pression is stopped or reduced and if the 
temptation is resisted to use the toxic (and 
immunosuppressive) chemotherapeutic regi-
mens that are customarily recommended by 
hemotologic oncologists. Lightening of immu-
nosuppression apparently led to disappear-
ance of the intestinal lesions in one of our liver 
recipients. The story of the appropriate treat-
ment of these pseudolymphomas has been 
most completely worked out in renal recip-
ients and is discussed by Dr. Tom Rosenthal 
elsewhere in this volume. 
SUMMARY 
Immunosuppression with cyclosporine and 
prednisone has transformed liver transplanta-
tion from an agonizingly difficult and highly 
unpredictable experimental undertaking to 
one that can be defended as a bona fide 
service. 
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